Mpilla GB, Philip PA, El-Rayes B, Azmi AS. Pancreatic neuroendocrine tumors: therapeutic challenges and research limitations. World J Gastroenterol. 2020;26(28):4036–54.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135(5):1469–92.

CAS  PubMed  Article  Google Scholar 

Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153–71.

CAS  PubMed  Article  Google Scholar 

Muscogiuri G, Altieri B, Albertelli M, Dotto A, Modica R, Barrea L, et al. Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. Endocrine. 2020;69(2):441–50.

CAS  PubMed  Article  Google Scholar 

Klöppel G, Couvelard A, Hruban R, Klimstra D, Komminoth P, Osamura R, et al. Neoplasms of the neuroendocrine pancreas. In: Lloyd R, Osamura R, Klöppel G, Rosai J, editors. WHO classification of tumours of endocrine organs. Lyon: IARC; 2017. p. 211–4.

Google Scholar 

Pezzilli R, Partelli S, Cannizzaro R, Pagano N, Crippa S, Pagnanelli M, et al. Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs): a systematic review. Adv Med Sci. 2016;61(1):147–53.

PubMed  Article  Google Scholar 

Lee L, Ito T, Jensen RT. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies. Expert Rev Anticancer Ther. 2019;19(12):1029–50.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ma ZY, Gong YF, Zhuang HK, Zhou ZX, Huang SZ, Zou YP, et al. Pancreatic neuroendocrine tumors: a review of serum biomarkers, staging, and management. World J Gastroenterol. 2020;26(19):2305–22.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Li W, Xu C, Ye Z. Prediction of pancreatic neuroendocrine tumor grading risk based on quantitative radiomic analysis of MR. Front Oncol. 2021;11:758062.

PubMed  PubMed Central  Article  Google Scholar 

He CB, Zhang Y, Cai ZY, Lin XJ. The impact of surgery in metastatic pancreatic neuroendocrine tumors: a competing risk analysis. Endocr Connect. 2019;8(3):239–51.

PubMed  PubMed Central  Article  Google Scholar 

Ye H, Xu HL, Shen Q, Zheng Q, Chen P. Palliative resection of primary tumor in metastatic nonfunctioning pancreatic neuroendocrine tumors. J Surg Res. 2019;243:578–87.

CAS  PubMed  Article  Google Scholar 

Nakano A, Hayano K, Tochigi T, Mashiko T, Masuoka Y, Yamamoto S, et al. Prediction of non-functioning pancreatic neuroendocrine tumor grades with fractal analysis of preoperative contrast-enhanced computed tomography images. Eur J Radiol. 2021;141:109803.

PubMed  Article  Google Scholar 

Kim DW, Kim HJ, Kim KW, Byun JH, Song KB, Kim JH, et al. Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT: comparison between grade 3 neuroendocrine carcinoma and grade 1/2 neuroendocrine tumour. Eur Radiol. 2015;25(5):1375–83.

PubMed  Article  Google Scholar 

Canellas R, Burk KS, Parakh A, Sahani DV. Prediction of pancreatic neuroendocrine tumor grade based on CT features and texture analysis. AJR Am J Roentgenol. 2018;210(2):341–6.

PubMed  Article  Google Scholar 

Kuzu OF, Noory MA, Robertson GP. The role of cholesterol in cancer. Cancer Res. 2016;76(8):2063–70.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Akbari-Fakhrabadi M, Heshmati J, Sepidarkish M, Shidfar F. Effect of sumac (Rhus Coriaria) on blood lipids: a systematic review and meta-analysis. Complement Ther Med. 2018;40:8–12.

PubMed  Article  Google Scholar 

Ganjali S, Banach M, Pirro M, Fras Z, Sahebkar A. HDL and cancer - causality still needs to be confirmed? Update 2020. Semin Cancer Biol. 2021;73:169–77.

CAS  PubMed  Article  Google Scholar 

Revilla G, Cedó L, Tondo M, Moral A, Pérez JI, Corcoy R, et al. LDL, HDL and endocrine-related cancer: from pathogenic mechanisms to therapies. Semin Cancer Biol. 2021;73:134–57.

CAS  PubMed  Article  Google Scholar 

Maran L, Hamid A, Hamid SBS. Lipoproteins as markers for monitoring cancer progression. J Lip. 2021;2021:8180424.

Google Scholar 

Wang C, Lin T, Wang X, Yu Z, Zhuge X, Cui W, et al. Low high-density lipoprotein cholesterol levels are associated with malignant intraductal papillary mucinous neoplasms: a multicenter study. Lip Health Dis. 2021;20(1):94.

CAS  Article  Google Scholar 

Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152–60.

CAS  PubMed  Article  Google Scholar 

Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2021;19(7):839–68.

CAS  Article  Google Scholar 

Huang B, Song BL, Xu C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metab. 2020;2(2):132–41.

PubMed  Article  Google Scholar 

Nowak C, Ärnlöv J. A Mendelian randomization study of the effects of blood lipids on breast cancer risk. Nat Commun. 2018;9(1):3957.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Beeghly-Fadiel A, Khankari NK, Delahanty RJ, Shu XO, Lu Y, Schmidt MK, et al. A Mendelian randomization analysis of circulating lipid traits and breast cancer risk. Int J Epidemiol. 2020;49(4):1117–31.

PubMed  Article  Google Scholar 

Choi YJ, Lee DH, Han KD, Shin CM, Kim N. Abdominal obesity, glucose intolerance and decreased high-density lipoprotein cholesterol as components of the metabolic syndrome are associated with the development of colorectal cancer. Eur J Epidemiol. 2018;33(11):1077–85.

CAS  PubMed  Article  Google Scholar 

Stevanovic M, Vekic J, Bogavac-Stanojevic N, Janac J, Stjepanovic Z, Zeljkovic D, et al. Significance of LDL and HDL subclasses characterization in the assessment of risk for colorectal cancer development. Biochem Med. 2018;28(3):030703.

Article  Google Scholar 

Zabłocka-Słowińska K, Płaczkowska S, Skórska K, Prescha A, Pawełczyk K, Porębska I, et al. Oxidative stress in lung cancer patients is associated with altered serum markers of lipid metabolism. PLoS One. 2019;14(4):e0215246.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Jamnagerwalla J, Howard LE, Allott EH, Vidal AC, Moreira DM, Castro-Santamaria R, et al. Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. Prostate Cancer Prostatic Dis. 2018;21(2):252–9.

CAS  PubMed  Article  Google Scholar 

Zhang D, Xi Y, Feng Y. Ovarian cancer risk in relation to blood lipid levels and hyperlipidemia: a systematic review and meta-analysis of observational epidemiologic studies. Eur J Cancer Prev. 2021;30(2):161–70.

CAS  PubMed  Article  Google Scholar 

Onwuka JU, Okekunle AP, Olutola OM, Akpa OM, Feng R. Lipid profile and risk of ovarian tumours: a meta-analysis. BMC Cancer. 2020;20(1):200.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Nam SY, Park BJ, Nam JH, Kook MC. Effect of helicobacter pylori eradication and high-density lipoprotein on the risk of de novo gastric cancer development. Gastrointest Endosc. 2019;90(3):448–56.

PubMed  Article  Google Scholar 

Feola T, Puliani G, Sesti F, Modica R, Centello R, Minotta R, et al. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study. J Endocrinol Investig. 2022;45(4):849–57.

CAS  Article  Google Scholar 

Wu J, Zhang C, Zhang G, Wang Y, Zhang Z, Su W, et al. Association between pretreatment serum Apolipoprotein A1 and prognosis of solid tumors in Chinese population: a systematic review and meta-analysis. Cell Physiol Biochem. 2018;51(2):575–88.

CAS  PubMed  Article  Google Scholar 

Ganjali S, Ricciuti B, Pirro M, Butler AE, Atkin SL, Banach M, et al. High-density lipoprotein components and functionality in cancer: state-of-the-art. Trends Endocrinol Metab. 2019;30(1):12–24.

CAS  PubMed  Article  Google Scholar 

Ossoli A, Wolska A, Remaley AT, Gomaraschi M. High-density lipoproteins: a promising tool against cancer. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867(1):159068.

CAS  PubMed  Article  Google Scholar 

Morin EE, Li XA, Schwendeman A. HDL in endocrine carcinomas: biomarker, drug carrier, and potential therapeutic. Front Endocrinol. 2018;9:715.

Article  Google Scholar 

Altieri B, Barrea L, Modica R, Muscogiuri G, Savastano S, Colao A, et al. Nutrition and neuroendocrine tumors: an update of the literature. Rev Endocr Metab Disord. 2018;19(2):159–67.

PubMed  Article  Google Scholar 

Barrea L, Muscogiuri G, Modica R, Altieri B, Pugliese G, Minotta R, et al. Cardio-metabolic indices and metabolic syndrome as predictors of clinical severity of gastroenteropancreatic neuroendocrine tumors. Front Endocrinol (Lausanne). 2021;12:649496.

Article  Google Scholar 

Qadan M, Ma Y, Visser BC, Kunz PL, Fisher GA, Norton JA, et al. Reassessment of the current American Joint Committee on Cancer staging system for pancreatic neuroendocrine tumors. J Am Coll Surg. 2014;218(2):188–95.